Boston Scientific [BSX]
As of 2026-07-29. Every date below is disclosed by the company or by a named medical congress. No date is inferred or fabricated. Undated items are listed separately and are not modelled.
| Date | Event | Why it matters | Confirms / refutes |
|---|---|---|---|
| Q3 2026 (mid-Oct, date not yet announced) | Q3 2026 earnings | First full quarter under the cut 6.5–8.0% organic guide. Tests whether Q2's guided 5–7% was the trough. | The implied-path test's required 6.2–7.2% organic |
| Q2 2026 (in progress) | ~$2.0bn share repurchase | CFO Monson, Q1 2026: "we intend to repurchase approximately $2 billion of our shares during the second quarter." Reduces share count ~2.9% → ~1,455m. | The 12-month target's share count |
| H2 2026 | Penumbra acquisition close | Shareholder vote held 2026-05-06; remaining regulatory clearances pending. Adds ~$1.45bn revenue and ~$12.3bn EV. Excluded from guidance and from this memo's EV. | State A re-test; EV convention |
| H2 2026 | Peripheral IVL below-the-knee indication launch | Above-the-knee already in expanded launch with positive physician feedback. | Vascular Therapies growth |
| 2026 (H2) | Next-generation ureteroscope launch | Urology grew only 1% organic in Q1 2026; this plus StoneSmart/LithoVue Elite is the stated fix. | Urology low-to-mid-single-digit FY guide |
| 2026 (H2) | FANAFLEX IDE initiation | Mahoney Q1 2026: "We anticipate initiating our IDE later this year." Gates the 2028 launch. | The post-2027 PFA pipeline |
| H1 2027 | FARAWAVE Ultra launch | The next-generation Farapulse catheter — the primary defence against Medtronic, J&J and Abbott in US PFA. | US EP reacceleration off mid-single-digit |
| H1 2027 | Coronary IVL (Fracture trial) US launch | Enrollment completed early 2026; data presented at EuroPCR 2026-05-19. | Interventional Cardiology |
| 2028 | FANAFLEX US launch | Large-area mapping/ablation for complex arrhythmias. First-in-human ELEVATE data presented at HRS 2026. | Beyond the 12-month horizon; supports the terminal growth rate |
| Date | Event | Market reaction |
|---|---|---|
| 2026-02-04 | Q4 2025 earnings; FY2026 organic guided 10–11% (down from ~15.5% delivered) | −17.59% |
| 2026-03-30 | CHAMPION (WATCHMAN) late-breaker at ACC — hit all primary and secondary endpoints | −9.02% |
| 2026-04-22 | Q1 2026 earnings | +8.99% |
| 2026-04-24 | (follow-through) | −5.51% |
| 2026-05-19 | Fracture trial (coronary IVL) data at EuroPCR | — |
| 2026-05-27 | (undiagnosed single-day move; no BSX disclosure located for this date) | −12.46% |